当前位置：
X-MOL 学术
›
Clin. Infect. Dis.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
Clinical Infectious Diseases ( IF 11.8 ) Pub Date : 2018-03-10 , DOI: 10.1093/cid/ciy171 Dale N Gerding 1 , Ciaran P Kelly 2 , Galia Rahav 3 , Christine Lee 4, 5 , Erik R Dubberke 6 , Princy N Kumar 7 , Bruce Yacyshyn 8 , Dina Kao 9 , Karen Eves 10 , Misoo C Ellison 11 , Mary E Hanson 12 , Dalya Guris 10 , Mary Beth Dorr 10
Clinical Infectious Diseases ( IF 11.8 ) Pub Date : 2018-03-10 , DOI: 10.1093/cid/ciy171 Dale N Gerding 1 , Ciaran P Kelly 2 , Galia Rahav 3 , Christine Lee 4, 5 , Erik R Dubberke 6 , Princy N Kumar 7 , Bruce Yacyshyn 8 , Dina Kao 9 , Karen Eves 10 , Misoo C Ellison 11 , Mary E Hanson 12 , Dalya Guris 10 , Mary Beth Dorr 10
Affiliation
Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies for C.difficile therapy (MODIFY) I/II data assessed bezlotoxumab efficacy in participants with characteristics associated with increased risk for rCDI.
中文翻译：
贝佐洛单抗预防复发风险增加的患者难治性梭状芽胞杆菌感染
贝佐洛单抗是一种针对艰难梭菌毒素B的人单克隆抗体，可预防成年rCDI高危成年人的艰难梭菌感染（CDI）复发（rCDI）。此事后对汇集单克隆抗体的分析C.艰难疗法（修改）I / II的数据评估了参与者与RCDI增加的风险相关联的特性bezlotoxumab功效。
更新日期：2018-03-10
中文翻译：
贝佐洛单抗预防复发风险增加的患者难治性梭状芽胞杆菌感染
贝佐洛单抗是一种针对艰难梭菌毒素B的人单克隆抗体，可预防成年rCDI高危成年人的艰难梭菌感染（CDI）复发（rCDI）。此事后对汇集单克隆抗体的分析C.艰难疗法（修改）I / II的数据评估了参与者与RCDI增加的风险相关联的特性bezlotoxumab功效。
京公网安备 11010802027423号